For the quarter ending 2025-09-30, FATE has $343,671K in assets. $40,622K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 40,622 | 41,249 | ||
| Accounts receivable | 682 | 1,395 | ||
| Short-term investments | 174,801 | 181,581 | ||
| Prepaid expenses and other current assets | 5,146 | 6,172 | ||
| Total current assets | 221,251 | 230,397 | ||
| Long-term investments | 10,305 | 26,097 | ||
| Property and equipment, net | 59,475 | 61,097 | ||
| Operating lease right-of-use assets | 42,413 | 43,814 | ||
| Restricted cash | 10,227 | 10,227 | ||
| Other assets | 0 | 0 | ||
| Total assets | 343,671 | 371,632 | ||
| Accounts payable | 3,504 | 4,040 | ||
| Accrued expenses | 17,571 | 18,182 | ||
| Cirm award liability, current portion | 2,280 | 795 | ||
| Deferred revenue | 5 | 0 | ||
| Operating lease liabilities, current portion | 4,751 | 5,656 | ||
| Total current liabilities | 28,111 | 28,673 | ||
| Cirm award liability, net of current portion | 6,590 | 5,600 | ||
| Operating lease liabilities, net of current portion | 74,494 | 75,675 | ||
| Stock price appreciation milestones | 410 | 320 | ||
| Preferred stock, 0.001 par value authorized shares - 5,000,000 at september 30, 2025 and december 31, 2024 class a convertible preferred shares issued and outstanding - 2,755,086 at september 30, 2025 and december 31, 2024 | 3 | 3 | ||
| Common stock, 0.001 par value authorized shares - 350,000,000 at september 30, 2025 and 250,000,000 at december 31, 2024 issued and outstanding - 115,336,697 at september 30, 2025 and 113,928,279 at december 31, 2024 | 115 | 115 | ||
| Additional paid-in capital | 1,735,730 | 1,730,869 | ||
| Accumulated other comprehensive income | 153 | 62 | ||
| Accumulated deficit | -1,501,935 | -1,469,685 | ||
| Total stockholders equity | 234,066 | 261,364 | ||
| Total liabilities and stockholders equity | 343,671 | 371,632 | ||
FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)